EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study

Silva Arslanian iD, Inge Gies, Bryan Goldman, Tobias Karlsson, Aaron S Kelly, Mette Skalshøi Kjær, Antje Körner iD, Mazen Noureddin, Martin Wabitsch, Nina M Harder-Lauridsen, Daniel Weghuber

Diabetes Care · 01.06.2026 · 49 (6) · 954-962

DOI: 10.2337/dc25-0824 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 26.11.2025. Verfasst von Silva Arslanian und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, Diabetes, and Metabolism, Center for Pediatric Research in Obesity and Metabolism, University of Pittsburgh Medi…. Hauptthemen laut MEDLINE: Insulin Resistance, Glucagon-Like Peptides, Obesity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE This secondary analysis of the Semaglutide Treatment Effect in People with obesity (STEP) TEENS (NCT04102189) study investigated the effect of semaglutide 2.4 mg versus placebo on insulin sensitivity and cardiometabolic risk factors. RESEARCH DESIGN AND METHODS The STEP TEENS phase 3a randomized study in adolescents (aged 12 to <18 years) with obesity demonstrated that once-weekly subcutaneous semaglutide 2.4 mg provided a significantly greater percentage reduction in BMI than placebo at week 68 (estimated difference −16.7 percentage points; P = 0.0001). This analysis investigated changes in insulin sensitivity and cardiometabolic risk factors from baseline to week 68. RESULTS Overall, 193 participants without type 2 diabetes were included in the analysis. Participants receiving semaglutide 2.4 mg (n = 129) compared with those receiving placebo (n = 64) had greater reductions from baseline in fasting serum insulin (−33.6% vs. −10.1%; P = 0.0012), homeostatic model assessment for insulin resistance (HOMA-IR) score (−35.0% vs. −5.3%; P = 0.0002), glycemic measures (glycated hemoglobin: P < 0.0001; fasting plasma glucose: P = 0.0181), alanine aminotransferase (ALT; −17.9% vs. −3.3%; P = 0.0232), waist-to-height ratio (P < 0.0001), triglycerides (P < 0.0001), LDL cholesterol (P = 0.0105), and total cholesterol (P < 0.0001). Moreover, greater improvements in insulin sensitivity, glycemic measures, and cardiometabolic risk factors were seen in semaglutide 2.4 mg recipients with BMI reductions of ≥20% versus <20%. CONCLUSIONS These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceGlucagon-Like PeptidesObesityHumansAdolescentFemaleMaleChildCardiometabolic Risk FactorsBlood GlucoseRisk Factors

Substanzen

Glucagon-Like PeptidesBlood Glucose

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, Diabetes, and Metabolism, Center for Pediatric Research in Obesity and Metabolism, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, PA.
  • Department of Pediatrics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Novo Nordisk Inc., Plainsboro, NJ.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, MN.
  • Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Zentrum München at Leipzig University and University Hospital Leipzig, Leipzig, Germany.

ORCID-Profile: Silva Arslanian, Antje Körner

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Arslanian, S., Gies, I., Goldman, B., Karlsson, T., Kelly, A. S., Skalshøi Kjær, M., Körner, A., Noureddin, M., Wabitsch, M., Harder-Lauridsen, N. M., & Weghuber, D. (2026). Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care, 49(6), 954-962. https://doi.org/10.2337/dc25-0824

Vancouver

Arslanian S, Gies I, Goldman B, Karlsson T, Kelly AS, Skalshøi Kjær M, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study. Diabetes Care. 2026;49(6):954-962. doi:10.2337/dc25-0824

BibTeX
@article{Arslanian2026,
  author = {Arslanian, Silva and Gies, Inge and Goldman, Bryan and Karlsson, Tobias and Kelly, Aaron S and Skalshøi Kjær, Mette and Körner, Antje and Noureddin, Mazen and Wabitsch, Martin and Harder-Lauridsen, Nina M and Weghuber, Daniel},
  title = {Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {6},
  pages = {954--962},
  doi = {10.2337/dc25-0824}
}
Kostenlos starten →